Drug Trial Radar · NCT02017613
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies
Last checked: Nov 19, 2026Latest source record: Jun 24, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Nov 2013
Primary completion
May 2016
Study completion May 2016
Sponsor
- Lead sponsor
- Rhizen Pharmaceuticals SAIndustry
- Sponsor type
- Industry
- First posted
- Dec 23, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with hematologic malignancies.
Conditions
- Lymphoma, B-Cell
- T-Cell Lymphoma
Interventions
RP6530Drug
Escalating doses starting at 25 mg BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) and pharmacokinetics (PK) of RP6530Time frame: 28 days
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Rhizen Trial Site
Paris, France
Rhizen Trial Site 1
Milan, Italy
Rhizen Trial Site 2
Milan, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.